Wegovy 7.2mg: Higher Doses Are Coming — Should You Wait or Start Now?

Novo Nordisk is seeking FDA approval for a higher dose of Wegovy — 7.2mg once weekly, triple the current maximum of 2.4mg. The STEP-UP trial results are impressive: 18.7% body weight loss at 72 weeks with the 7.2mg dose, compared to 15.6% with the existing 2.4mg dose and 3.9% with placebo.

Those numbers are significant. They put higher-dose Wegovy in the same territory as tirzepatide (Zepbound), which achieved 19.5–20.9% weight loss at its highest doses. Naturally, patients are asking: should I wait for the higher dose before starting?

The Short Answer: Start Now

No. In almost every clinical scenario, starting treatment now is better than waiting. Here's why:

1. You Can Dose Up Later

If you start Wegovy at the current dosing schedule and the 7.2mg dose gets approved, your doctor can increase your dose. You don't lose the progress you've already made — you build on it. GLP-1 titration is designed to go up, not start over.

2. The Approval Timeline Is Uncertain

While Novo Nordisk has submitted the higher dose to the FDA, there's no guaranteed approval date. Regulatory reviews can take months. Waiting for a "maybe" while your health continues to be affected by excess weight is not a sound clinical strategy.

3. Obesity Is a Progressive Condition

The metabolic damage of carrying excess weight compounds over time. Every month of effective treatment reduces cardiovascular risk, improves insulin sensitivity, and protects your joints. Delaying treatment by 6–12 months has real costs.

4. The Higher Dose Isn't for Everyone

Higher doses mean more medication and potentially more side effects. Many patients achieve clinically meaningful results (≥10% body weight loss) at the current 2.4mg dose. Not everyone will need — or tolerate — 7.2mg.

What the STEP-UP Data Actually Shows

Dose	Weight Loss at 72 Weeks	Difference vs. Current Max
Wegovy 7.2mg	18.7%	+3.1 percentage points
Wegovy 2.4mg (current max)	15.6%	—
Placebo	3.9%	—

An additional 3.1 percentage points of weight loss is clinically meaningful — for a 250-pound person, that's roughly 8 extra pounds. But it's not a fundamentally different medication. It's the same semaglutide at a higher dose. If you respond well to semaglutide at 2.4mg, you'll likely respond even better at 7.2mg when it becomes available.

Who Might Benefit Most from 7.2mg?

The higher dose is most likely to matter for patients who:

• Plateau at 2.4mg — You've been at the maximum dose for 3+ months and weight loss has stalled
• Have severe obesity (BMI ≥ 40) — Higher starting weight often requires more aggressive treatment
• Are considering switching to tirzepatide — If the reason for switching is wanting more weight loss, a higher semaglutide dose may achieve that without changing medications
• Have significant weight-related comorbidities — Cardiovascular disease, severe sleep apnea, or type 2 diabetes where additional weight loss would improve outcomes

What About Compounded Semaglutide?

Patients on compounded semaglutide may wonder whether they're missing out. Here's the reality: compounded semaglutide is the same active ingredient as Wegovy, and compounding pharmacies have more dosing flexibility than brand-name pens. Some compounded providers already offer doses above 2.4mg, though this is off-protocol and should only be done under direct medical supervision.

If you're currently on compounded semaglutide and responding well, there's no clinical reason to switch to brand-name Wegovy for the higher dose. The molecule is the same.

What to Tell Your Doctor

If the 7.2mg dose comes up in your appointment, here's how to frame the conversation:

If you haven't started yet: "I've read about the higher 7.2mg dose of Wegovy being reviewed. I don't want to wait for that — I'd like to start treatment now and consider adjusting my dose later if needed."

If you've plateaued: "I've been at 2.4mg for [X months] and my weight loss has stalled. When the 7.2mg dose becomes available, would I be a candidate? In the meantime, should we consider other options?"

If you're on compounded semaglutide: "I'm on compounded semaglutide at [dose]. Do I need to think about switching to brand-name if the higher dose is approved, or can I achieve similar results with my current provider?"

The Bottom Line

A higher dose of Wegovy is coming. That's good news for patients who need more from their treatment. But it's not a reason to delay starting. The best time to begin treating obesity is now — not when the next incremental improvement arrives. Start, titrate, and if a higher dose becomes available and appropriate for you, your doctor can adjust your plan accordingly.